Q0518 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ0518
- Long description
- Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days
- Short description
- Supply fee hiv prep oral 90
- Pricing indicator
46Priced by carrier (not otherwise classified / individual determination)- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- January 2, 2024
- Last change
- January 1, 2025 – No change
- Termination date
- December 31, 2024
Frequently asked questions
What is HCPCS code Q0518?
Q0518 is a HCPCS Level II code for pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days. It was discontinued on December 31, 2024.
Does Medicare cover Q0518?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q0510 – Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
- Q0511 – Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
- Q0512 – Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
- Q0513 – Pharmacy dispensing fee for inhalation drug(s); per 30 days
- Q0514 – Pharmacy dispensing fee for inhalation drug(s); per 90 days
- Q0515 – Injection, sermorelin acetate, 1 microgram
- Q0516 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-days
- Q0517 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
- Q0519 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days
- Q0520 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days
- Q0521 – Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription
- Q1004 – New technology intraocular lens category 4 as defined in federal register notice
- Q1005 – New technology intraocular lens category 5 as defined in federal register notice
- Q2004 – Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2009 – Injection, fosphenytoin, 50 mg phenytoin equivalent
- Q2017 – Injection, teniposide, 50 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.